About Acyl-CoA 6-desaturase
Acyl-CoA 6-desaturase (FADS2) is a protein
from Homo sapiens identified by UniProt accession
O95864, 444 residues long.
MolForge cross-references it against 0 known binders and
446 disease associations.
Target properties
| Protein name | Acyl-CoA 6-desaturase |
| UniProt accession | O95864 |
| Gene | FADS2 |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (446)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- multiple sclerosis · score 0.47
- lysosomal storage disease · score 0.46
- Parkinson disease · score 0.46
- Alzheimer disease · score 0.46
- phosphatidylcholine measurement · score 0.40
- phosphatidylethanolamine measurement · score 0.39
- serum metabolite measurement · score 0.37
- phosphatidylinositol measurement · score 0.37
- blood metabolite measurement · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95864-F1 | alphafold | PREDICTED | 94.98 | — |
Amino-acid sequence (444 residues)
MGKGGNQGEG AAEREVSVPT FSWEEIQKHN LRTDRWLVID RKVYNITKWS IQHPGGQRVI GHYAGEDATD AFRAFHPDLE FVGKFLKPLL IGELAPEEPS QDHGKNSKIT EDFRALRKTA EDMNLFKTNH VFFLLLLAHI IALESIAWFT VFYFGNGWIP TLITAFVLAT SQAQAGWLQH DYGHLSVYRK PKWNHLVHKF VIGHLKGASA NWWNHRHFQH HAKPNIFHKD PDVNMLHVFV LGEWQPIEYG KKKLKYLPYN HQHEYFFLIG PPLLIPMYFQ YQIIMTMIVH KNWVDLAWAV SYYIRFFITY IPFYGILGAL LFLNFIRFLE SHWFVWVTQM NHIVMEIDQE AYRDWFSSQL TATCNVEQSF FNDWFSGHLN FQIEHHLFPT MPRHNLHKIA PLVKSLCAKH GIEYQEKPLL RALLDIIRSL KKSGKLWLDA YLHK
Explore Acyl-CoA 6-desaturase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets